Literature DB >> 10511014

Psychopharmacology in autism.

L Y Tsai1.   

Abstract

Autism is a neurobiological disorder. The core clinical features of autism include impairment in social interaction, impairments in verbal and nonverbal communication, and restricted, repetitive, and stereotyped patterns of behavior, interests, and activities. Autism often has coexisting neuropsychiatric disorders, including seizure disorders, attention deficit hyperactivity disorder, affective disorders, anxiety disorder, obsessive-compulsive disorder, and Tourette disorder. No etiology-based treatment modality has been developed to cure individuals with autism. However, comprehensive intervention, including parental counseling, behavior modification, special education in a highly structured environment, sensory integration training, speech therapy, social skill training, and medication, has demonstrated significant treatment effects in many individuals with autism. Findings from preliminary studies of major neurotransmitters and other neurochemical agents strongly suggest that neurochemical factors play a major role in autism. The findings also provide the rationale for psychopharmacotherapy in individuals with autism. This article reviews studies of neurochemical systems and related psychopharmacological research in autism and related neuropsychiatric disorders. Clinical indications for pharmacotherapy are described, and uses of various medications are suggested. This article also discusses new avenues of investigation that may lead to the development of more effective medication treatments in persons with autism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10511014     DOI: 10.1097/00006842-199909000-00008

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  14 in total

1.  Prevalence and correlates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit/hyperactivity disorder.

Authors:  Thomas W Frazier; Paul T Shattuck; Sarah Carter Narendorf; Benjamin P Cooper; Mary Wagner; Edward L Spitznagel
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-12-13       Impact factor: 2.576

Review 2.  Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature.

Authors:  J Helen Yoo; Maria G Valdovinos; Dean C Williams
Journal:  J Autism Dev Disord       Date:  2007-01-13

3.  Treating anxiety disorders in children with high functioning autism spectrum disorders: a controlled trial.

Authors:  Anne Marie Chalfant; Ron Rapee; Louisa Carroll
Journal:  J Autism Dev Disord       Date:  2006-12-15

4.  Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007-2008.

Authors:  Rebecca E Rosenberg; David S Mandell; Janet E Farmer; J Kiely Law; Alison R Marvin; Paul A Law
Journal:  J Autism Dev Disord       Date:  2010-03

5.  Pharmacotherapy of target symptoms in autistic spectrum disorders.

Authors:  P J Santosh; G Baird
Journal:  Indian J Pediatr       Date:  2001-05       Impact factor: 1.967

6.  Adolescents and Adults with Autism with and without Co-morbid Psychiatric Disorders: Differences in Maternal Well-Being.

Authors:  Sheilah R Kring; Jan S Greenberg; Marsha Mailick Seltzer
Journal:  J Ment Health Res Intellect Disabil       Date:  2008-04-01

7.  The Novel Potential Therapeutic Utility of Montelukast in Alleviating Autistic Behavior Induced by Early Postnatal Administration of Thimerosal in Mice.

Authors:  Lobna A Abdelzaher; Ola A Hussein; I E M Ashry
Journal:  Cell Mol Neurobiol       Date:  2020-04-17       Impact factor: 5.046

8.  Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders.

Authors:  David S Mandell; Knashawn H Morales; Steven C Marcus; Aubyn C Stahmer; Jalpa Doshi; Daniel E Polsky
Journal:  Pediatrics       Date:  2008-03       Impact factor: 7.124

9.  Reduced excitatory neurotransmission and mild autism-relevant phenotypes in adolescent Shank3 null mutant mice.

Authors:  Mu Yang; Ozlem Bozdagi; Maria Luisa Scattoni; Markus Wöhr; Florence I Roullet; Adam M Katz; Danielle N Abrams; David Kalikhman; Harrison Simon; Leuk Woldeyohannes; James Y Zhang; Mark J Harris; Roheeni Saxena; Jill L Silverman; Joseph D Buxbaum; Jacqueline N Crawley
Journal:  J Neurosci       Date:  2012-05-09       Impact factor: 6.167

10.  Animal model integration to AutDB, a genetic database for autism.

Authors:  Ajay Kumar; Rachna Wadhawan; Catherine Croft Swanwick; Ravi Kollu; Saumyendra N Basu; Sharmila Banerjee-Basu
Journal:  BMC Med Genomics       Date:  2011-01-27       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.